[1] Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research[J]. Nature, 2003,422(6934): 835-847.
[2] Feero WG, Guttmacher AE, Collins FS. Genomic
medicine—an updated primer[J]. N Engl J, 2010, 362(21):2001-2011.
[3] ENCODE Project Consortium.
The ENCODE (ENCyclopedia of DNA Elements) Project[J]. Science,2004, 306(5696): 636-640.
[4] Becker F, van El CG, Ibarreta D, et al. Genetic testing and common disorders in a public health
framework: how to assess relevance and possibilities.
Background Document to the ESHG recommendations on genetic testing and common
disorders[J]. Eur J Hum Genet, 2011,19(Suppl 1): S6-S44.
[5] Callier SL, Abudu R, Mehlman MJ, et al. Ethical, legal, and social implications of personalized genomic medicine research: current literature and suggestions for the future[J]. Bioethics, 2016,30(9):698-705.
[6] Ojha RP, Thertulien R. Health care policy issues as a result of the genetic
revolution: implications for public health[J]. Am J Public Health, 2005,95(3): 385-388.
[7] Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease[J]. Circ Res, 2017,120(6): 923-940.
[8] Hood L, Rowen L. The Human Genome Project: big
science transforms biology and medicine[J]. Genome Med, 2013, 5(9):79.
[9] Lejeune C, Amado IF, DEFIDIAG study group, et al. Valuing genetic and genomic testing in France: current challenges and latest evidence[J]. J Community Genet, 2022,13(5): 477-485.
[10] AVIESAN. Genomic Medicine
France 2025[EB/OL]. (2017)[2023-10-31].https://sante.gouv.fr/IMG/pdf/genomic_medicine_france_2025.pdf.
[11] Lévy Y. Genomic medicine 2025: France in the race for precision medicine[J]. Lancet,2016, 388(10062): 2872.
[12] Lethimonnier F,Levy Y. Genomic medicine France 2025[J]. Ann Oncol, 2018,29(4): 783-784.
[13] Auzanneau C, Bacq D, Bellera C, et al. Feasibility of high-throughput
sequencing in clinical routine cancer care: lessons from the cancer
pilot project of the France Genomic Medicine 2025 plan[J]. ESMO Open, 2020, 5(4): e000744.
[14] Béziat V, Li J, Lin JX. et al. A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity[J]. Sci Immunol, 2018,3(24): eaat4956.
[15] Hamroun D, Kato S, Ishioka C, et al. The UMD TP53 database
and website: update and revisions[J]. Hum Mutat, 2006, 27(1): 14-20.
[16] Casanova JL. Human genetic
basis of interindividual variability in the course of infection[J]. Proc Natl Acad Sci U S A, 2015, 112(5):E7118-E7127.
[17] Zhang Q, Bastard P, Liu Z. et al. Inborn
errors of type I IFN immunity in patients with life-threatening COVID-19[J]. Science, 2020, 370(6515): eabd4570.
[18] AVIESAN. The French Plan for
Genomic Medicine 2025[EB/OL]. [2023-10-31]. https://pfmg2025.aviesan.fr/presentation.
[19] MULTIPLI. About the France
Genomic Medicine 2025 Plan[EB/OL]. [2023-10-31]. https://multipli.inserm.fr/the-multipli-program.
[20] Khan W, Varma Saripella G, Ludwig T, et al. MACARON: a python framework to
identify and reannotate multi-base affected codons in whole genome/exome sequence data[J]. Bioinformatics, 2018,34(19): 3396-3398.
[21] Cambon-Thomsen A, Thorisson GA, Mabile L. The role of a bioresource research impact factor as an
incentive to share human bioresources[J]. Nat Genet, 2011,43(6): 503-504.
[22] Gozlan D, Mathieu M, de Montgolfier S, et al. Towards more informed consent: Making information understandable[J]. Med Sci (Paris), 2023,39(8-9): 650-657.
[23] Dinart D, Italiano A, Laurent-Puig P, et al. Programme MULTIPLI: développement d′essais
cliniques par séquençage à haut débit et pour des cancers avancés[J]. Revue
d'Épidémiologie et de Santé Publique, 2018,66(S3): S145.
[24] Foster MW, Mulvihill JJ, Sharp RR. Evaluating
the utility of personal genomic information[J]. Genet Med, 2009,11(8): 570-574.
[25] Binquet C, Lejeune C, Faivre L, et al. Genome sequencing for genetics diagnosis of patients with
intellectual disability: The DEFIDIAG Study[J]. Front Genet, 2022, 12; 766964.
[26] Lejeune C, Robert-Viard C, Meunier-Beillard N, et al. The economic, medical and psychosocial consequences of whole genome sequencing
for the genetic diagnosis of patients with intellectual disability: the DEFIDIAG study protocol[J]. Front Genet, 2022,13: 852472.
[27] Herzig AF, Velo-Suárez L, Le Folgoc G, et al. Evaluation of saliva as a source of accurate whole-genome and microbiome sequencing data[J]. Genet Epidemiol, 2021.45(5): 537-548.
[28] Philippe N, Legendre M, Doutre G, et al. Pandoraviruses: amoeba viruses with
genomes up to 2.5 Mb reaching that of parasitic eukaryotes[J]. Science, 2013, 341(6143): 281-286.
[29] Schulz F, Yutin N, Ivanova NN, et al. Giant viruses with an expanded complement of translation
system components[J]. Science,2017, 356(6333):82-85.
|